Get the Stockscreener App
0.00
100.00%
-17.42
After Hours:
17.25
17.25
+
Puretech Health Plc Adr stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
See More
Previous Close:
$17.42
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$424.03M
Revenue:
$4.66M
Net Income/Loss:
$-110.22M
P/E Ratio:
0.00
EPS:
-4.5634
Net Cash Flow:
$-84.82M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$19.92
Puretech Health Plc Adr Stock (PRTC) Company Profile
Name
Puretech Health Plc Adr
Sector
Industry
Phone
-
Address
-
Compare PRTC vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRTC
Puretech Health Plc Adr
|
0.00 | 424.03M | 4.66M | -110.22M | -84.82M | -4.5634 |
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Puretech Health Plc Adr Stock (PRTC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
Puretech Health Plc Adr Stock (PRTC) Latest News
PureTech Health issues shares to executives under RSU plan - Investing.com
PRTCY | PURETECH HEALTH PLC ADR Institutional Ownership - Quiver Quantitative
PRTCY | PURETECH HEALTH PLC ADR Stock Data, Price & News - Quiver Quantitative
PureTech Health issues shares to non-executive directors - Investing.com
PureTech Health issues shares to executives under vesting plan - Investing.com
PureTech Health's Celea Therapeutics Launches Phase 3 SURPASS-IPF Trial for Deupirfenidone in Idiopathic Pulmonary Fibrosis - Kalkine Media
PureTech Health Directors Invest Heavily with GBP 1.19 Share Acquisitions - Kalkine Media
Why PureTech Health (LSE:PRTC) Directors Are Increasing Their Shareholdings - Kalkine Media
PureTech spins out Celea with $180m financing for IPF drug - Investing.com
0VQ0 Forecast — Price Target — Prediction for 2027 - TradingView
PureTech Health ADR (PRTC) Edges Higher Amidst Modest UptickBackspread Trade - dars.gov.et
PureTech Health (PRTCY) Dividend Yield (TTM) - Zacks Investment Research
PureTech Health (PRTCY) Market Cap - Zacks Investment Research
PRTCY: PureTech HealthComparison to Industry - Zacks Investment Research
PureTech Health (PRTCY) - Zacks Investment Research
PRTC News | PURETECH HEALTH PLCADR (NASDAQ:PRTC) - ChartMill
PRTC Stock Price, Quote & Chart | PURETECH HEALTH PLCADR (NASDAQ:PRTC) - ChartMill
PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference - ChartMill
PureTech Health Plc (LSE:PRTC) Share Price, History, & News - The Twelfth Magpie
PureTech Health Seaport listing lifts FTSE 350 sentiment surge? - Kalkine Media
PureTech Health H2 Earnings Call Highlights - Yahoo Finance
PureTech Health (NASDAQ:PRTC) Posts Quarterly Earnings Results, Beats Estimates By $0.59 EPS - MarketBeat
PureTech Announces Intention to Voluntarily Delist American Depos - The National Law Review
[20-F] PureTech Health plc Files Annual Report (Foreign Issuer) | PRTC SEC FilingForm 20-F - Stock Titan
Earnings call transcript: PureTech Health’s mixed FY2025 results spark stock drop - Investing.com
PureTech Health (PRTC) ends Nasdaq ADS listing, focuses trading on LSE - Stock Titan
PureTech to Exit Nasdaq Listing and Consolidise Trading in London - Yahoo Finance UK
PureTech Health to delist ADSs from Nasdaq, focus on LSE - Investing.com
PureTech Health to delist ADSs from Nasdaq, focus on LSE By Investing.com - Investing.com South Africa
PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange - marketscreener.com
PureTech Announces Annual Results for Year Ended December 31, 2025 - ChartMill
PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors - ChartMill
PureTech Health (PRTC) Expected to Announce Earnings on Wednesday - MarketBeat
0VQ.DE Stock Price, Quote & Chart | PURETECH HEALTH PLC (FRA:0VQ) - ChartMill
PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Short Interest Up 30.8% in March - MarketBeat
PureTech Health: Notice of Results - ChartMill
Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsight - GlobeNewswire Inc.
PureTech Founded Entity Seaport Therapeutics Announces Positive Proof of Concept Topline Results from Ongoing Phase 1 Trial of GlyphAgo™ in Healthy Volunteers - ChartMill
PureTech publishes Phase 2b trial results for IPF drug candidate - Investing.com
Is PureTech Health in FTSE AIM 100? - Kalkine Media
Short Interest in PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Rises By 140.8% - MarketBeat
Short Interest in Citizens Bancorp of Virginia, Inc. (OTCMKTS:CZBT) Grows By 141.4% - Defense World
Pacer American Energy Independence ETF (NYSEARCA:USAI) Sees Large Increase in Short Interest - Defense World
PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans - ChartMill
Lansdowne Partners UK LLP Takes Position in PureTech Health PLC Sponsored ADR $PRTC - MarketBeat
PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Short Interest Up 36.2% in February - MarketBeat
PureTech Health in the FTSE landscape as technical momentum shifts - Kalkine Media
PureTech to Present at the Leerink Partners Global Healthcare Conference - ChartMill
PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Short Interest Update - MarketBeat
PureTech CEO to present at J.P. Morgan Healthcare Conference - Investing.com
PureTech Health appoints Robert Lyne as permanent CEO By Investing.com - Investing.com UK
Puretech Health Plc Adr Stock (PRTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.21%
1.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):